Kane Biotech (CVE:KNE) Stock Price Up 9.1% – Here’s What Happened

Kane Biotech Inc. (CVE:KNE) shares were up 9.1% on Tuesday . The stock traded as high as C$0.13 and last traded at C$0.12. Approximately 243,500 shares were traded during trading, an increase of 90% from the average daily volume of 127,871 shares. The stock had previously closed at C$0.11.

Kane Biotech Price Performance

The firm has a 50-day simple moving average of C$0.13 and a two-hundred day simple moving average of C$0.14. The company has a market capitalization of C$15.90 million, a price-to-earnings ratio of -4.00 and a beta of 0.52. The company has a current ratio of 0.82, a quick ratio of 0.39 and a debt-to-equity ratio of 1,164.24.

Kane Biotech (CVE:KNE) last announced its quarterly earnings results on Thursday, August 29th. The company reported C($0.01) earnings per share for the quarter. The business had revenue of C$0.62 million during the quarter.

About Kane Biotech

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.